Edition:
United Kingdom

People: Concert Pharmaceuticals Inc (CNCE.OQ)

CNCE.OQ on NASDAQ Stock Exchange Global Market

10.91USD
21 Jun 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$10.91
Open
--
Day's High
--
Day's Low
--
Volume
100
Avg. Vol
78,437
52-wk High
$20.11
52-wk Low
$9.23

Barrett, Ronald 

Dr. Ronald W. Barrett, Ph.D., is an Independent Director of Concert Pharmaceuticals Inc. Dr. Barrett was a founder of XenoPort, Inc., a public biopharmaceutical company, and served as its Chief Executive Officer from 2001 to 2015, its Chief Scientific Officer from 1999 to 2001 and as a member of its board of directors from 1999 to 2015. Prior to XenoPort, Dr. Barrett held various positions at Affymax Research Institute, a drug discovery company now owned by GlaxoSmithKline plc, and Abbott Laboratories, a healthcare company. During the last five years, Dr. Barrett also served as a member of the board of directors of XenoPort. Dr. Barrett received a B.S. from Bucknell University and a Ph.D. in Pharmacology from Rutgers University. We believe that Dr. Barrett’s industry and board experience, including his experience as the chief executive officer of a publicly traded biopharmaceutical company, make him a key contributor to our Board of Directors.

Basic Compensation

Total Annual Compensation, USD 51,367
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 133,748
Fiscal Year Total, USD 185,115

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Richard Aldrich

205,613

Roger Tung

4,607,850

Marc Becker

2,450,530

Nancy Stuart

1,908,030

James Cassella

1,960,240

Thomas Auchincloss

205,613
As Of  31 Dec 2018